Payment overview · 2025
General Payments
$454.32
20 reported records · 7 companies
Healthcare provider profile · identity verified
Lydia Adams, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FAYETTEVILLE, TN · NPI 1528618162
Verified facts
What the public records show
CMS Open Payments records show Lydia Adams, APRN received $454.32 in general payments during 2025 across 20 reported records.
Astellas Pharma US Inc accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $226.72 | 49.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.93 | 12.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $44.16 | 9.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.32 | 9.5% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.94 | 8.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.40 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.85 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $454.32 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $226.72 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 36 |
| Famotidine | Famotidine | 145 | 41 |
| Lisinopril | Lisinopril | 129 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 121 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 36 |
| Gabapentin | Gabapentin | 113 | 27 |
| Prednisone | Prednisone | 110 | 76 |
| Furosemide | Furosemide | 105 | 34 |
| Spironolactone | Spironolactone | 103 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 19 |
| Potassium Chloride | Potassium Chloride | 87 | 30 |
| Losartan Potassium | Losartan Potassium | 84 | 24 |
| Sertraline Hcl | Sertraline Hcl | 81 | 14 |
| Atenolol | Atenolol | 67 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 65 | 21 |
| Metformin Hcl | Metformin Hcl | 62 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 13 |
| Azelastine Hcl | Azelastine Hcl | 49 | 24 |
| Trazodone Hcl | Trazodone Hcl | 49 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 16 |
| Jardiance | Empagliflozin | 43 | 15 |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 42 | 17 |
| Sucralfate | Sucralfate | 42 | 15 |
| Allopurinol | Allopurinol | 41 | 12 |
| Baclofen | Baclofen | 41 | 12 |
| Carvedilol | Carvedilol | 41 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Celecoxib | Celecoxib | 38 | 13 |
| Eliquis | Apixaban | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 15 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 19 |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Omeprazole | Omeprazole | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 13 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Clonidine Hcl | Clonidine Hcl | 30 | 19 |
| Meloxicam | Meloxicam | 30 | 12 |
| Ozempic | Semaglutide | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Januvia | Sitagliptin Phosphate | 29 | 11 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 21 |
| Gemtesa | Vibegron | 24 | suppressed |
| Colchicine | Colchicine | 23 | 11 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Otezla | Apremilast | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $454.32 · 20 records | Astellas Pharma US Inc | Auvelity, CAPLYTA, MOUNJARO, ONPATTRO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error